Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Seer will showcase its AI-driven multi-cancer screening approach and next-generation proteomics tools at the ASMS 2026 conference in San Diego. The company will preview findings from a collaboration with Korea University analyzing over 20,000 clinical plasma samples for multi-cancer screening.
Key figures
- Proteins profiled hubp
- 10,000
- Clinical samples analyzed
- 20,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.